Latest news with #XVIVOPerfusionAB
Yahoo
a day ago
- Business
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire
Yahoo
15-04-2025
- Business
- Yahoo
Conference Call on Interim Report January-March 2025
GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025. The presentation will be held in English. Time: Thursday, April 24 at 2.00 pm CET / 8.00 am EST If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions Participants from XVIVO:Christoffer Rosenblad, CEOKristoffer Nordström, CFO A press release containing XVIVO's interim report January-March 2025 will be released on April 24, 2025 at 7.30 am CET / 1.30 am EST. Before the conference call, slides will be available at the company web page, April 15, 2025MölndalXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments Conference call on Interim Report January-March 2025 SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire
